news Tissue damage and genetic mutations interact to drive pancreatic cancer, finds study 4 February 2021 | By Hannah Balfour (Drug Target Review) New research shows tissue damage to cells carrying KRAS mutations induces epigenetic changes that promote pancreatic cancer.
news Study provides insight into muscle wasting in cancer patients 4 February 2021 | By Victoria Rees (Drug Target Review) Using a mouse model, researchers found that cancer progression led to fewer skeletal muscle ribosomes, likely explaining muscle wasting.
news Researchers identify how Zika infects foetuses and a potential drug to prevent it 4 February 2021 | By Hannah Balfour (Drug Target Review) According to scientists, maternal cells act as a reservoir for Zika, enabling the virus to pass from mother to foetus during pregnancy.
news Deletions in SARS-CoV-2 Spike protein drive antibody escape, study shows 4 February 2021 | By Victoria Rees (Drug Target Review) Researchers have found that SARS-CoV-2 evades immune responses by deleting parts of its genetic sequence that encode for the Spike protein.
news Could bile acids play a role in Parkinson’s pathogenesis? 3 February 2021 | By Hannah Balfour (Drug Target Review) A new study suggests bile acids may act as a valuable biomarker for diagnosing and tracking the progression of Parkinson's disease.
news Majority retain COVID-19 antibodies for six months after infection 3 February 2021 | By Victoria Rees (Drug Target Review) A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
news HIV drugs could be repurposed to prevent the onset of macular degeneration 2 February 2021 | By Hannah Balfour (Drug Target Review) Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.
news Targeting the HCF-1 protein causes cancerous cells to self-destruct 1 February 2021 | By Hannah Balfour (Drug Target Review) Disrupting the interaction between the MYC oncogene and its co-factor, host cell factor (HCF)–1, was sufficient to cause Burkitt’s lymphoma cells to self-destruct in vivo.
news N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study 1 February 2021 | By Hannah Balfour (Drug Target Review) The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
news UK offers genomics expertise to identify new SARS-CoV-2 variants 29 January 2021 | By Victoria Rees (Drug Target Review) The UK Government has said genomics expertise will be offered to countries around the world to identify new variants of SARS-CoV-2.
news Biomarkers predict Alzheimer’s five years before onset 29 January 2021 | By Hannah Balfour (Drug Target Review) The discovery of early plasma biomarkers for Alzheimer's disease could transform outcomes by enabling patients to begin treatment early.
news New ion trap used to create highly accurate mass spectrometer 29 January 2021 | By Victoria Rees (Drug Target Review) Researchers have developed a new mass spectrometer that uses rotation frequencies of ionised molecules to measure mass with high accuracy.
news T cells target broad range of SARS-CoV-2 epitopes, study shows 29 January 2021 | By Victoria Rees (Drug Target Review) A study has found that T cells combat SARS-CoV-2 by targeting many sites on the coronavirus, not just the Spike protein.
whitepaper Whitepaper: Why BioPharma Lifecycle Management? 28 January 2021 | By IDBS In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.
news New database to track neurological symptoms of COVID-19 28 January 2021 | By Hannah Balfour (Drug Target Review) NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.